Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Cancer Research UK embarks on new initiative to unravel genetic secrets behind cancers

Unravelling the genetic secrets behind a range of cancers - from understanding how certain genes control cancer to determining how the disease evades treatment - is the aim of a new initiative from Cancer Research UK.

18 Nov 2011

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

MDxHealth total revenues decrease 7% for third quarter 2011

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the third quarter and for the nine months ended September 30, 2011.

17 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Veronica Cappalonga, 28, knows a lot about living with cancer. Diagnosed at age 6 with leukemia and at 22 with a malignant brain tumor, the Los Angeles (Mar Vista area) resident will walk in the Nov. 6 Heroes of Hope Race for Brain Tumor Research - not only to help fundraise, but also to show that survivors can fight these diseases with dignity.

29 Oct 2011

Nestin-driven oncolytic viruses show effectiveness in glioblastoma models

A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.

28 Oct 2011

Mobile phones and brain cancer: the link may not be strong says new study

The largest study till date has refuted earlier fears that link mobile phone use to brain cancer. However experts say the risk can't be ruled out.

20 Oct 2011

Subjects with borderline elevated IgE levels less likely to develop glioma

A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.

19 Oct 2011

Brain tumour discovery offers drug treatment hope

Australian scientists have played a key role in the identification of a new biochemical mechanism that allows brain tumours to survive and grow, offering hope of new drug treatments for some of the most aggressive tumours.

17 Oct 2011

FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.

12 Oct 2011

UCLA's screening system can target stem cells responsible for glioblastoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.

12 Oct 2011

MD Anderson initiates orders of Cesium-131 to help control intermediate risk prostate cancer

IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that MD Anderson Cancer Center has initiated orders of Cesium-131 brachytherapy (internal radiation therapy) seeds as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer.

11 Oct 2011

Loyola's SSOM receives $100,000 grant for research into pediatric leukemia

Loyola University Chicago Stritch School of Medicine (SSOM) today received a $100,000 grant to support research to treat an aggressive form of pediatric leukemia.

4 Oct 2011

UAB Comprehensive Cancer Center receives NCI grant to renew support for cancer research program

The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.

1 Oct 2011

World's first treatment of metastasized brain cancer uses IsoRay's Cesium-131 brachytherapy seeds

IsoRay, a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world's first treatment of metastasized brain cancer using IsoRay's Cesium-131 brachytherapy seeds.

26 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011

Stanford Hospital & Clinics inaugurates new Brain Tumor Center

Today, Stanford Hospital & Clinics inaugurates its new Brain Tumor Center, framing its considerable corps of top-notch specialists into a treatment team driven by expertise, experience and compassion.

22 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011